Fig. 1: Hyperactive phospho-ERK (pERK) in patients with ESCC is associated with poor prognosis.
From: Blocking STAT3 signaling augments MEK/ERK inhibitor efficacy in esophageal squamous cell carcinoma
A Frequencies of upstream mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) signaling-related gene amplification (EGFR, ERBB2, FGFR, NGFR, KRAS, and NRAS) in ESCC from The Cancer Genome Atlas. B pERK immunohistochemistry (IHC) in tumor and para-carcinoma tissues of patients with ESCC. Representative images of pERK expression in normal and ESCC tissues (n = 72) and statistical results. Scale bar, 100 μm. Data are presented as the mean ± standard deviation (SD). ***P < 0.001. C Representative low and high expression of pERK in tumor tissues obtained using IHC. D Kaplan–Meier survival curve of overall survival based on the expression of pERK (n = 301) in patients with ESCC. E Western blotting shows pERK expression after different concentrations of U0126 treatment in six ESCC cell lines. F Colony formation assays for six ESCC cell lines after different concentrations of U0126 treatment for 7–10 days. The growth inhibition ratio was calculated according to the number of colonies formed. G U0126 drug sensitivity IC50 values in six ESCC cell lines.
